Intravesical therapy is a well-established treatment option for non-muscle-invasive bladder cancer (NMIBC).
Choosing the appropriate intravesical agent, schedule and duration of treatment has long been an area of debate. We review the intravesical agents that are currently used in the management of NMIBC and examine the indications and limitations of their use. Given the relative high rates of toxicity, failure and non-completion of traditional treatments we also examine some of the newer treatment options available.
Written by:
Logan C, Brown M, Hayne D. Are you the author?
School of Surgery, University of Western Australia, Fremantle, Western Australia, Australia.
Reference: BJU Int. 2012 Dec;110 Suppl 4:12-21.
doi: 10.1111/j.1464-410X.2012.11619.x
PubMed Abstract
PMID: 23194118
UroToday.com Bladder Cancer Section